Criswell Mark H, Hu Wen-Zheng, Steffens Timothy J, Li Ruihong, Margaron Philippe
Retina Service Research Laboratories, Department of Ophthalmology, Indiana University School of Medicine, 702 Rotary Cir, Indianapolis, IN 46202-5175, USA.
Arch Ophthalmol. 2008 Jul;126(7):946-52. doi: 10.1001/archopht.126.7.946.
To evaluate the prophylactic effect of intravitreal pegaptanib sodium on choroidal neovascularization membrane (CNVM) development and compare its performance with that of triamcinolone acetonide.
In drug-treated and control groups, CNVMs were induced by laser trauma. Immediately after undergoing the laser procedure, animals received intravitreal injections of pegaptanib sodium, 8 or 17 mug; triamcinolone acetonide, 200 mug; or a vehicle solution. After 21 days, fluorescein angiography was performed. The CNVM mean diameters and radial thicknesses were measured histologically.
Mean CNVM diameters were 10% to 13% smaller in pegaptanib-treated eyes and 43% smaller in triamcinolone-treated eyes compared with laser-only control eyes. Late-stage fluorescein angiography leakage scores, on a scale of 0 to 3, suggested a statistical difference between triamcinolone- (0.6) and pegaptanib(8 microg)-treated (1.5) groups compared with the laser-only control group (2.0). The CNVM mean thicknesses were greater in the pegaptanib(8 microg)- (79 microm) and pegaptanib(17 microg)-treated (71 microm) groups and significantly smaller in the triamcinolone-treated group (26 microm) compared with the laser-only control group (67 microm).
In this animal model of choroidal neovascularization, intravitreal pegaptanib exhibited marginal or no effect on CNVM development; whereas intravitreal triamcinolone evoked robust inhibition of CNVMs. Clinical Relevance Pegaptanib treatment may be insufficient to prevent CNVM formation.
评估玻璃体内注射培加他尼钠对脉络膜新生血管膜（CNVM）形成的预防作用，并将其与曲安奈德的性能进行比较。
在药物治疗组和对照组中，通过激光损伤诱导CNVM形成。激光手术后立即给动物玻璃体内注射8或17微克培加他尼钠、200微克曲安奈德或赋形剂溶液。21天后，进行荧光素血管造影。通过组织学测量CNVM的平均直径和径向厚度。
与仅接受激光治疗的对照组相比，培加他尼治疗组的CNVM平均直径小10%至13%，曲安奈德治疗组的小43%。晚期荧光素血管造影渗漏评分（范围为0至3）显示，与仅接受激光治疗的对照组（2.0）相比，曲安奈德治疗组（0.6）和培加他尼（8微克）治疗组（1.5）之间存在统计学差异。与仅接受激光治疗的对照组（67微米）相比，培加他尼（8微克）治疗组（79微米）和培加他尼（17微克）治疗组的CNVM平均厚度更大，曲安奈德治疗组（26微米）的则明显更小。
在这个脉络膜新生血管动物模型中，玻璃体内注射培加他尼对CNVM形成的影响很小或没有影响；而玻璃体内注射曲安奈德能显著抑制CNVM。临床意义：培加他尼治疗可能不足以预防CNVM的形成。
